Fulcrum Therapeutics Stock Forecast

Sell candidate since Jun 01, 2026 Loss -42.52%

The Fulcrum Therapeutics, Inc. stock price gained 9.50% on the last trading day (Friday, 5th Jun 2026), rising from $3.37 to $3.69. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 12.12% from a day low at $3.30 to a day high of $3.70. The price has risen in 7 of the last 10 days but is still down by -44.01% for this period. Volume fell on the last day by -5 million shares and in total, 0 shares were bought and sold for approximately $0 . You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $3.03 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -23.75% during the next 3 months and, with a 90% probability hold a price between $2.31 and $5.41 at the end of this 3-month period.

FULC Signals & Forecast

A buy signal was issued from a pivot bottom point on Tuesday, June 02, 2026, and so far it has risen 17.52%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Fulcrum Therapeutics, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $4.80 and $6.65. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may not be. The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Fulcrum Therapeutics, Inc. stock

On the downside, the stock finds support just below today's level from accumulated volume at $3.37 and $3.22. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Fulcrum Therapeutics, Inc. finds support just below today's level at $3.37. If this is broken, then the next support from accumulated volume will be at $3.22 and $3.14.

In general the stock tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the stock During the last day, the stock moved $0.400 between high and low, or 12.12%. For the last week the stock has had daily average volatility of 9.37%

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (FULC) For The Upcoming Trading Day Of Monday 8th

For the upcoming trading day on Monday, 8th we expect Fulcrum Therapeutics, Inc. to open at $3.56, and during the day (based on 14 day Average True Range), to move between $3.41 and $3.97, which gives a possible trading interval of +/-$0.551 (+/-16.12%) up or down from last closing price. If Fulcrum Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 16.12% move between the lowest and the highest trading price during the day.

With no resistance above and support from accumulated volume @ $3.37, some $0.320 (8.67%) from the current price of $3.69, our system finds the risk reward attractive.

Is Fulcrum Therapeutics, Inc. stock A Buy?

Fulcrum Therapeutics, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -4.029 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on June 8, 2026 - $3.56 ( 3.43%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk